Why the study?
Does P2Y receptor antagonism prevent ADP-mediated release of VEGF and endostatin from platelets?
Population
Minimally altered whole blood (WB) and platelet rich plasma (PRP) from healthy volunteers
Comparison
ADP alone or in combination with a P2Y… vs Control
Design
Preclinical
Authors
Loading...
P2Y antagonism may limit platelet angiogenesis in vitro; animal data leave open in vivo or clinical relevance.
Does P2Y receptor antagonism prevent ADP-mediated release of VEGF and endostatin from platelets?
P2Y receptor antagonism abrogates ADP-mediated proangiogenic VEGF release from platelets, highlighting a potential mechanism for regulating platelet-mediated angiogenesis.
Bambace et al. (2010) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: